
Floor J Backes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6809915/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy. Gynecologic Oncology, 2022, 164, 628-638.	0.6	4
2	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
3	A Novel Estrogen Receptor Î ² Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition. Cancers, 2022, 14, 2311.	1.7	7
4	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecologic Oncology, 2021, 160, 161-168.	0.6	24
5	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecologic Oncology, 2021, 160, 817-826.	0.6	51
6	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. Gynecologic Oncology, 2021, 160, 827-834.	0.6	20
7	Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers. Current Oncology Reports, 2021, 23, 75.	1.8	5
8	Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?. Oncologist, 2021, 26, 1044-1051.	1.9	7
9	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecologic Oncology, 2021, 162, 619-625.	0.6	7
10	Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy. Gynecologic Oncology Reports, 2021, 38, 100872.	0.3	1
11	ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2â^'/â^' Ovarian Cancer Cells. Molecular Cancer Therapeutics, 2020, 19, 199-210.	1.9	43
12	Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. American Journal of Obstetrics and Gynecology, 2020, 222, 60.e1-60.e7.	0.7	58
13	Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. Neoplasia, 2020, 22, 484-496.	2.3	7
14	Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research, 2020, 26, 3928-3935.	3.2	154
15	Dermatofibrosarcoma protuberans: A rare and devastating tumor of the vulva. Gynecologic Oncology Reports, 2019, 28, 9-11.	0.3	7
16	Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecologic Oncology, 2019, 153, 496-499.	0.6	50
17	The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: A multi-disciplinary, multi-institutional cohort study. American Journal of Surgery, 2019, 218, 275-280.	0.9	12
18	Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. Gynecologic Oncology, 2019, 153, 255-258.	0.6	10

#	Article	IF	CITATIONS
19	Mismatch repair deficiency identifies patients with highâ€intermediate–risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. Cancer, 2019, 125, 398-405.	2.0	35
20	Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology, 2019, 152, 554-559.	0.6	14
21	Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecologic Oncology, 2019, 152, 316-321.	0.6	27
22	Role of Minimally Invasive Surgery in Gynecologic Malignancies. , 2018, , 560-578.e11.		1
23	Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency. International Journal of Gynecological Cancer, 2018, 28, 59-68.	1.2	38
24	Surgical outcomes among elderly women with endometrial cancerÂtreated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology, 2018, 218, 109.e1-109.e11.	0.7	43
25	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research, 2018, 24, 777-783.	3.2	171
26	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology, 2018, 148, 174-180.	0.6	83
27	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal of Clinical Oncology, 2018, 36, 2044-2051.	0.8	313
28	Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival. Gynecologic Oncology, 2018, 150, 38-43.	0.6	9
29	Functional characterization of recurrent <i>FOXA2</i> mutations seen in endometrial cancers. International Journal of Cancer, 2018, 143, 2955-2961.	2.3	6
30	Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. Gynecologic Oncology, 2017, 144, 451-455.	0.6	2
31	The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion. American Journal of Surgical Pathology, 2017, 41, 49-55.	2.1	44
32	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic Oncology, 2017, 146, 247-253.	0.6	23
33	Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncology, 2017, 146, 405-415.	0.6	298
34	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecologic Oncology, 2017, 145, 519-525.	0.6	52
35	Synucleinâ€Î³ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer, 2017, 123, 1144-1155.	2.0	11
36	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic Oncology, 2017, 144, 96-100.	0.6	21

#	Article	IF	CITATIONS
37	Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 396-401.	0.6	6
38	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecologic Oncology, 2017, 146, 588-595.	0.6	77
39	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. Gynecologic Oncology, 2017, 147, 110-114.	0.6	46
40	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer, 2017, 123, 985-993.	2.0	13
41	Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?. Gynecologic Oncology, 2017, 144, 290-293.	0.6	13
42	Management of a rapidly enlarging new adnexal mass: a rare case of desmoplastic small round cell tumor of the ovary arising in pregnancy. Gynecologic Oncology Reports, 2016, 17, 23-25.	0.3	6
43	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2016, 34, 3062-3068.	0.8	141
44	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecologic Oncology, 2016, 142, 139-143.	0.6	57
45	Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI. Gynecologic Oncology, 2016, 140, 405-408.	0.6	9
46	A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2016, 23, 429-434.	0.3	17
47	Late side effects of robotic surgery. Gynecologic Oncology, 2016, 140, 375-376.	0.6	0
48	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecologic Oncology, 2016, 141, 312-317.	0.6	75
49	Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. International Journal of Gynecological Cancer, 2016, 26, 35-42.	1.2	6
50	Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 438-445.	1.1	15
51	The role of sentinel lymph nodes in endometrial and cervical cancer. Journal of Surgical Oncology, 2015, 112, 753-760.	0.8	21
52	Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications. International Journal of Gynecological Cancer, 2015, 25, 1271-1276.	1.2	18
53	Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour) Tj ETQq1 1 International Journal of Gynecological Cancer, 2015, 25, 1331-1336.	0.784314 1.2	rgBT /Overloc 15
54	The Use of Transvaginal Ultrasound in Type II Endometrial Cancer. International Journal of Gynecological Cancer, 2015, 25, 858-862.	1.2	14

#	Article	IF	CITATIONS
55	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecologic Oncology, 2015, 136, 246-253.	0.6	104
56	Predicting Inpatient Stay Lasting 2 Midnights or Longer AfterÂRobotic Surgery for Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2015, 22, 583-589.	0.3	7
57	Intraoperative radiation therapy (IORT) for gynecologic malignancies. Gynecologic Oncology, 2015, 138, 449-456.	0.6	16
58	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecologic Oncology, 2015, 138, 689-693.	0.6	9
59	Noncatalytic <i>PTEN</i> missense mutation predisposes to organ-selective cancer development in vivo. Genes and Development, 2015, 29, 1707-1720.	2.7	29
60	Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2015, 138, 614-619.	0.6	9
61	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 4301-4308.	0.8	163
62	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
63	Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. Gynecologic Oncology, 2014, 135, 90-94.	0.6	22
64	Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?. Gynecologic Oncology, 2014, 135, 95-99.	0.6	25
65	Hysterectomy for the Treatment of Gynecologic Malignancy. Clinical Obstetrics and Gynecology, 2014, 57, 115-127.	0.6	9
66	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study. International Journal of Gynecological Cancer, 2014, 24, 682-686.	1.2	16
67	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma. International Journal of Gynecological Cancer, 2014, 24, S83-S89.	1.2	51
68	Salpingectomy, why not?. American Journal of Obstetrics and Gynecology, 2014, 210, 385-386.	0.7	7
69	Imaging across the Life Span: Innovations in Imaging and Therapy for Gynecologic Cancer. Radiographics, 2014, 34, 1062-1081.	1.4	5
70	Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecologic Oncology, 2014, 133, 43-47.	0.6	35
71	Training the Next Generation of Robotic Surgeons Using Guided Mentorship: A Randomized Controlled Trial. Journal of Minimally Invasive Gynecology, 2014, 21, 1075-1079.	0.3	8
72	Response to Dr. Carter's letter to the editor regarding "Short and long term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging― Gynecologic Oncology, 2013, 128, 148.	0.6	0

#	Article	IF	CITATIONS
73	Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: Time to change back?. Gynecologic Oncology, 2013, 128, 60-64.	0.6	27
74	Neuroendocrine carcinoma of the uterine cervix: The role of multimodality therapy in early-stage disease. Gynecologic Oncology, 2013, 129, 135-139.	0.6	28
75	Reducing readmissions after robotic surgical management of endometrial cancer:A potential for improved quality care. Gynecologic Oncology, 2013, 131, 508-511.	0.6	20
76	Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. Gynecologic Oncology, 2013, 128, 309-315.	0.6	44
77	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. International Journal of Gynecological Cancer, 2013, 23, 833-838.	1.2	7
78	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genetics in Medicine, 2012, 14, 670-680.	1.1	40
79	Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?. Gynecologic Oncology, 2012, 127, 362-366.	0.6	9
80	Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecologic Oncology, 2012, 125, 546-551.	0.6	64
81	The Impact of Body Weight on Ovarian Cancer Outcomes. International Journal of Gynecological Cancer, 2011, 21, 1601-1605.	1.2	27
82	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecologic Oncology, 2011, 121, 269-272.	0.6	49
83	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. Gynecologic Oncology, 2011, 123, 532-536.	0.6	40
84	Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American Journal of Obstetrics and Gynecology, 2011, 204, 466-478.	0.7	343
85	Lynch Syndrome. Clinical Obstetrics and Gynecology, 2011, 54, 199-214.	0.6	31
86	Corrigendum to "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer―[Gynecologic Oncology 111 (2008) 461–466]. Gynecologic Oncology, 2010, 119, 603.	0.6	0
87	Overview of epithelial ovarian cancer and updates in management strategies. Expert Review of Obstetrics and Gynecology, 2009, 4, 383-399.	0.4	1
88	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 2009, 114, 486-490.	0.6	68
89	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. Familial Cancer, 2009, 8, 483-487.	0.9	14
90	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. Obstetrics and Gynecology, 2009, 114, 530-536.	1.2	62

#	Article	IF	CITATIONS
91	Robotic radical hysterectomy and pelvic lymphadenectomy for uterine rhabdomyosarcoma. Journal of Robotic Surgery, 2008, 2, 197-200.	1.0	7
92	Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecologic Oncology, 2008, 111, 461-466.	0.6	52
93	Robotic Trocar Site Small Bowel Evisceration After Gynecologic Cancer Surgery. Obstetrics and Gynecology, 2008, 112, 462-464.	1.2	39